CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)

Chr t(11;14)

Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Mabtas (rituximab biosimilar)

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)

P2, N=33, Not yet recruiting, University of Washington

1 month ago

New P2 trial

Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (clinicaltrials.gov)

P2, N=18, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Dec 2025

1 month ago

Trial completion date

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)

P2, N=53, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Mar 2029

1 month ago

Enrollment open • Trial completion date • Trial primary completion date

clonoSEQ

Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov)

P3, N=102, Not yet recruiting, SWOG Cancer Research Network

1 month ago

New P3 trial

doxorubicin hydrochloride • cyclophosphamide • vincristine • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)

2ms

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (clinicaltrials.gov)

P1/2, N=84, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jun 2026

2 months ago

Enrollment open • Trial initiation date

BRAF (B-raf proto-oncogene)

Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)

3ms

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P1, N=50, Active, not recruiting, Mayo Clinic | Trial completion date: May 2027 --> May 2028

3 months ago

Trial completion date

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)

3ms

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=30, Not yet recruiting, University of Washington | Initiation date: Sep 2025 --> Dec 2025

3 months ago

Trial initiation date

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)

3ms

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)

P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2025 --> Aug 2026

3 months ago

Trial completion date

CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)

Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)

4ms

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=25, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

BCL2 (B-cell CLL/lymphoma 2)

carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)

4ms

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=18, Not yet recruiting, University of Washington

4 months ago

New P2 trial

BCL2 (B-cell CLL/lymphoma 2)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)